Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Healthtrust
Daiichi Sankyo
Argus Health
UBS
Fuji
Farmers Insurance
Baxter
Cipla

Generated: February 22, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR SUTENT

« Back to Dashboard

Clinical Trials for Sutent

Trial ID Title Status Sponsor Phase Summary
NCT00137436 Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer Completed Pfizer Phase 1/Phase 2 This is a multi-center, open-label, Phase 1/2 study of SU011248 (sunitinib malate, SUTENT) in combination with docetaxel and prednisone for the first-line treatment of metastatic hormone-refractory prostate cancer (mHRPC).
NCT00246571 Study Of SU011248 Versus Chemotherapy For Patients With Previously Treated Triple Receptor Negative Breast Cancer Completed Pfizer Phase 2 The purpose of this study is to compare progression free survival for SU011248 [sutent (sunitinib malate)] versus standard of care therapy in patients with previously treated, advanced, triple receptor negative (ER, PR, HER2) locally recurrent or metastatic breast cancer.
NCT00265317 A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone Completed Pfizer Phase 2 This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen
NCT00291577 Study Of SU011248 In Combination With Docetaxel In Patients With Metastatic Breast Cancer Completed Pfizer Phase 1 This study is to evaluate the safety of SU011248 (Sunitinib/Sutent) in combination with docetaxel in patients with metastatic or locally recurrent breast cancer who have not received chemotherapy treatment in the advanced disease setting.
NCT00299741 Study of SU11248 in Men With Advanced Prostate Cancer Completed United States Department of Defense Phase 2 - There are nearly 30,000 deaths per year in the United States from prostate cancer, making this a large and important target patient population for new cancer treatments. - SU011248 is an exciting, new, experimental drug that inhibits a number of proteins, or more specifically receptor tyrosine kinases, in tumor cells. These proteins are active in cellular pathways that are important for development and growth of a variety of different cancers. The targets of SU011248 include the receptors for vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and others. By blocking the VEGF and PDGF pathways, SU011248 can induce death of the blood vessels that nourish the cancer cells and death of the cancer cells themselves. - SU011248 has demonstrated significant anti-tumor activity in renal cell carcinoma, gastrointestinal stromal tumors, and other cancers. Its effect against prostate cancer has not been studied to date. - This study is directed at two populations of men with advanced prostate cancer: 1. Men with advanced prostate cancer who have a rising PSA despite hormone therapy, but have not yet received any chemotherapy. 2. Men with metastatic prostate cancer who have received prior chemotherapy (with a docetaxel-based regimen) and have increasing disease following chemotherapy. - Men in this study will receive SU011248 on a six-week repeating schedule, with four weeks of daily treatment followed by a two-week rest. The goals of the study are: 1. to determine whether SU011248 is an important therapeutic agent in men with advanced prostate cancer, and 2. to identify predictive markers of anti-cancer activity within individual subjects that would allow selective treatment of appropriate subjects in the future.
NCT00299741 Study of SU11248 in Men With Advanced Prostate Cancer Completed Massachusetts General Hospital Phase 2 - There are nearly 30,000 deaths per year in the United States from prostate cancer, making this a large and important target patient population for new cancer treatments. - SU011248 is an exciting, new, experimental drug that inhibits a number of proteins, or more specifically receptor tyrosine kinases, in tumor cells. These proteins are active in cellular pathways that are important for development and growth of a variety of different cancers. The targets of SU011248 include the receptors for vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and others. By blocking the VEGF and PDGF pathways, SU011248 can induce death of the blood vessels that nourish the cancer cells and death of the cancer cells themselves. - SU011248 has demonstrated significant anti-tumor activity in renal cell carcinoma, gastrointestinal stromal tumors, and other cancers. Its effect against prostate cancer has not been studied to date. - This study is directed at two populations of men with advanced prostate cancer: 1. Men with advanced prostate cancer who have a rising PSA despite hormone therapy, but have not yet received any chemotherapy. 2. Men with metastatic prostate cancer who have received prior chemotherapy (with a docetaxel-based regimen) and have increasing disease following chemotherapy. - Men in this study will receive SU011248 on a six-week repeating schedule, with four weeks of daily treatment followed by a two-week rest. The goals of the study are: 1. to determine whether SU011248 is an important therapeutic agent in men with advanced prostate cancer, and 2. to identify predictive markers of anti-cancer activity within individual subjects that would allow selective treatment of appropriate subjects in the future.
NCT00304200 Temodar and Sutent as Therapy for Melanoma Terminated Pfizer Phase 1/Phase 2 This study is designed to evaluate the safety and appropriate dose of the combination of Temodar and Sutent as first-line therapy for patients with metastatic malignant melanoma (Phase 1). Once the safety and appropriate dose is determined, additional patients will be studied at that dose to determine if there is clinical benefit as determined by the primary end-point of progression-free survival (PFS) at 6 months and additional secondary endpoints (Phase II).
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Sutent

Condition Name

Condition Name for Sutent
Intervention Trials
Renal Cell Carcinoma 16
Metastatic Renal Cell Carcinoma 12
Carcinoma, Renal Cell 9
Kidney Cancer 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Sutent
Intervention Trials
Carcinoma, Renal Cell 55
Carcinoma 49
Kidney Neoplasms 13
Breast Neoplasms 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Sutent

Trials by Country

Trials by Country for Sutent
Location Trials
United States 419
Canada 56
Japan 39
Italy 36
Germany 33
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Sutent
Location Trials
Texas 31
California 21
Ohio 19
New York 19
North Carolina 18
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Sutent

Clinical Trial Phase

Clinical Trial Phase for Sutent
Clinical Trial Phase Trials
Phase 4 3
Phase 3 12
Phase 2/Phase 3 1
[disabled in preview] 126
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Sutent
Clinical Trial Phase Trials
Completed 66
Terminated 21
Recruiting 20
[disabled in preview] 41
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Sutent

Sponsor Name

Sponsor Name for Sutent
Sponsor Trials
Pfizer 76
M.D. Anderson Cancer Center 11
National Cancer Institute (NCI) 9
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Sutent
Sponsor Trials
Other 132
Industry 123
NIH 10
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
McKesson
Johnson and Johnson
AstraZeneca
Queensland Health
Teva
Julphar
Fish and Richardson
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.